Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model

Antiviral Research

Volumn 86, Issue 3, 2010, Pages 261-267

  Julander, Justin G ^a   Jha, Ashok K ^b   Choi, Jung Ae ^a   Jung, Kie Hoon ^a   Smee, Donald F ^a   Morrey, John D ^a   Chu, Chung K ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

2 C methylcytidine; Antiviral; Hamster; Treatment; Yellow fever virus

Indexed keywords

2' METHYLCYTIDINE; ALANINE AMINOTRANSFERASE; PLACEBO; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FLAVIVIRUS INFECTION; HAMSTER; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; VERO CELL; VIRUS INHIBITION; VIRUS TITRATION; WEIGHT CHANGE; YELLOW FEVER FLAVIVIRUS;

ALANINE TRANSAMINASE; ANIMALS; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BODY WEIGHT; CERCOPITHECUS AETHIOPS; CRICETINAE; CYTIDINE; FEMALE; LIVER; MESOCRICETUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERO CELLS; VIRAL LOAD; YELLOW FEVER; YELLOW FEVER VIRUS;

CRICETINAE; HEPATITIS C VIRUS; YELLOW FEVER VIRUS;

EID: 77952669442     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.03.004     Document Type: Article

References (38)

1. Bassit L., Grier J., Bennett M., Schinazi R.F. Combinations of 2′-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir. Chem. Chemother. 2008, 19:25-31.
2. Buckwold V.E., Wei J., Huang Z., Huang C., Nalca A., Wells J., Russell J., Collins B., Ptak R., Lang W., Scribner C., Blanchett D., Alessi T., Langecker P. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res. 2007, 73:118-125.
3. Carroll S.S., Olsen D.B. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord. Drug Targets 2006, 6:17-29.
4. Charlier N., Leyssen P., De Clercq E., Neyts J. Rodent models for the study of therapy against flavivirus infections. Antiviral Res. 2004, 63:67-77.
5. Clark J.L., Hollecker L., Mason J.C., Stuyver L.J., Tharnish P.M., Lostia S., Mcbrayer T.R., Schinazi R.F., Watanabe K.A., Otto M.J., Furman P.A., Stec W.J., Patterson S.E., Pankiewicz K.W. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 2005, 48:5504-5508.
6. Coelmont L., Paeshuyse J., Windisch M.P., De Clercq E., Bartenschlager R., Neyts J. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob. Agents Chemother. 2006, 50:3444-3446.
7. Domingo C., Niedrig M. Safety of 17D derived yellow fever vaccines. Expert Opin. Drug Saf. 2009, 8:211-221.
8. Fogt J., Januszczyk P., Framski G., Onishi T., Izawa K., De Clercq E., Neyts J., Boryski J. Synthesis and antiviral activity of novel derivatives of 2′-beta-C-methylcytidine. Nucl. Acids Symp. Ser. (Oxf.) 2008, 605-606.
9. Goris N., De Palma A., Toussaint J.F., Musch I., Neyts J., De Clercq K. 2′-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 2007, 73:161-168.
10. Hayes E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:967-971.
11. Julander J.G., Furuta Y., Shafer K., Sidwell R.W. Activity of T-1106 in a hamster model of yellow fever virus infection. Antimicrob. Agents Chemother. 2007, 51:1962-1966.
12. Julander J.G., Morrey J.D., Blatt L.M., Shafer K., Sidwell R.W. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Res. 2007, 73:140-146.
13. Julander J.G., Shafer K., Smee D.F., Morrey J.D., Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 2009, 53:202-209.
14. Keller T.H., Chen Y.L., Knox J.E., Lim S.P., Ma N.L., Patel S.J., Sampath A., Wang Q.Y., Yin Z., Vasudevan S.G. Finding new medicines for flaviviral targets. Novartis Found. Symp. 2006, 277:102-114. (discussion 114-109, 251-103).
15. Lawitz E., Nguyen T., Younes Z., Santoro J., Gitlin N., Mceniry D., Chasen R., Goff J., Dieterich D., Knox S., Kleber K., Belanger B., Brown N.A. Clearance of HCV RNA with valopicitabine (NM) plus peg-interferon in treatment-naive patients with HCV-1 infection: results at 24 and 48 weeks. J. Hepatol. 2007, 46:S9.
16. Liu-Young G., Kozal M.J. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS 2008, 22:449-457.
17. Meier K.C., Gardner C.L., Khoretonenko M.V., Klimstra W.B., Ryman K.D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 2009, 5:e1000614.
18. Monath T.P. Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull. Soc. Pathol. Exot. 2006, 99:341-347.
19. Monath T.P. Treatment of yellow fever. Antiviral Res. 2008, 78:116-124.
20. Monath T.P., Brinker K.R., Chandler F.W., Kemp G.E., Cropp C.B. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am. J. Trop. Med. Hyg. 1981, 30:431-443.
21. Murakami E., Bao H., Ramesh M., Mcbrayer T.R., Whitaker T., Micolochick Steuer H.M., Schinazi R.F., Stuyver L.J., Obikhod A., Otto M.J., Furman P.A. Mechanism of activation of beta-d-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 2007, 51:503-509.
22. Murakami E., Niu C., Bao H., Micolochick Steuer H.M., Whitaker T., Nachman T., Sofia M.A., Wang P., Otto M.J., Furman P.A. The mechanism of action of beta-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-d-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 2008, 52:458-464.
23. Neyts J. Selective inhibitors of hepatitis C virus replication. Antiviral Res. 2006, 71:363-371.
24. Pierra C., Amador A., Benzaria S., Cretton-Scott E., D'amours M., Mao J., Mathieu S., Moussa A., Bridges E.G., Standring D.N., Sommadossi J.P., Storer R., Gosselin G. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J. Med. Chem. 2006, 49:6614-6620.
25. Pierra C., Benzaria S., Amador A., Moussa A., Mathieu S., Storer R., Gosselin G. Nm 283, an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids 2005, 24:767-770.
26. Reed L.J., Muench C.H. A simple method of estimating fifty percent endpoint. Am. J. Hyg. 1938, 27:493-497.
27. Sbrana E., Xiao S.Y., Guzman H., Ye M., Travassos Da Rosa A.P., Tesh R.B. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am. J. Trop. Med. Hyg. 2004, 71:306-312.
28. Sbrana E., Xiao S.Y., Popov V.L., Newman P.C., Tesh R.B. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. Am. J. Trop. Med. Hyg. 2006, 74:1084-1089.
29. Shannon W.M., Arnett G., Westbrook L., Shealy Y.F., O'dell C.A., Brockman R.W. Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza Type A viruses. Antimicrob. Agents Chemother. 1981, 20:769-776.
30. Sidwell R.W., Barnard D.L., Day C.W., Smee D.F., Bailey K.W., Wong M.H., Morrey J.D., Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 2007, 51:845-851.
31. Sidwell R.W., Huffman J.H. Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Appl. Microbiol. 1971, 22:797-801.
32. Stuyver L.J., Mcbrayer T.R., Tharnish P.M., Clark J., Hollecker L., Lostia S., Nachman T., Grier J., Bennett M.A., Xie M.Y., Schinazi R.F., Morrey J.D., Julander J.G., Furman P.A., Otto M.J. Inhibition of hepatitis C replicon RNA synthesis by beta-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. 2006, 17:79-87.
33. Tesh R.B., Guzman H., Da Rosa A.P., Vasconcelos P.F., Dias L.B., Bunnell J.E., Zhang H., Xiao S.Y. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J. Infect. Dis. 2001, 183:1431-1436.
34. Tomori O. Yellow fever: the recurring plague. Crit. Rev. Clin. Lab. Sci. 2004, 41:391-427.
35. Toniutto P., Fabris C., Bitetto D., Fornasiere E., Rapetti R., Pirisi M. Valopicitabine dihydrochloride: a specific polymerase inhibitor of hepatitis C virus. Curr. Opin. Investig. Drugs 2007, 8:150-158.
36. Tuboi S.H., Costa Z.G., Da Costa Vasconcelos P.F., Hatch D. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. Trans. R. Soc. Trop. Med. Hyg. 2007, 101:169-175.
37. Xiao S.Y., Zhang H., Guzman H., Tesh R.B. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J. Infect. Dis. 2001, 183:1437-1444.
38. Yin Z., Chen Y.L., Schul W., Wang Q.Y., Gu F., Duraiswamy J., Kondreddi R.R., Niyomrattanakit P., Lakshminarayana S.B., Goh A., Xu H.Y., Liu W., Liu B., Lim J.Y., Ng C.Y., Qing M., Lim C.C., Yip A., Wang G., Chan W.L., Tan H.P., Lin K., Zhang B., Zou G., Bernard K.A., Garrett C., Beltz K., Dong M., Weaver M., He H., Pichota A., Dartois V., Keller T.H., Shi P.Y. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20435-20439.